Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report.

Di Lorenzo G, Pagliuca M, Perillo T, Zarrella A, Verde A, De Placido S, Buonerba C.

Medicine (Baltimore). 2016 Feb;95(5):e2598. doi: 10.1097/MD.0000000000002598.

2.

Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.

Park JH, Lee JL.

Cancer Chemother Pharmacol. 2015 Feb;75(2):247-54. doi: 10.1007/s00280-014-2640-4. Epub 2014 Nov 27.

PMID:
25428517
3.

Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.

Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C.

J Urol. 2016 Feb;195(2):254-63. doi: 10.1016/j.juro.2015.06.115. Epub 2015 Sep 26. Review.

PMID:
26410730
4.

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.

Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret V, George C.

Cancer. 2009 Sep 15;115(18):4110-7. doi: 10.1002/cncr.24460.

5.
6.

The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.

Palacka P, Mego M, Obertova J, Chovanec M, Sycova-Mila Z, Mardiak J.

Klin Onkol. 2014;27(6):429-33.

PMID:
25493582
7.

Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients.

Di Lorenzo G, Montesarchio V, Autorino R, Bellelli T, Longo N, Imbimbo C, Morelli E, Giannarini G, Mirone V, De Placido S.

Cancer. 2009 Feb 1;115(3):517-23. doi: 10.1002/cncr.24055.

8.

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.

Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, Rolland F, Delgado FM, Longerey B, James N.

Br J Cancer. 2006 May 22;94(10):1395-401.

9.

Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report.

Sternberg JJ, Bracken RB, Handel PB, Johnson DE.

JAMA. 1977 Nov 21;238(21):2282-7.

PMID:
578848
10.

[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].

Song Y, Yang L, Zhou A, Chi Y, Wang J.

Zhonghua Zhong Liu Za Zhi. 2014 Mar;36(3):212-6. Chinese.

PMID:
24785283
11.

Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.

Bellmunt J, Cos J, Clèries R, Pérez M, Ribas A, Eres N, Murio JE, Margarit C, Baselga J.

Cancer Invest. 2002;20(5-6):673-85.

PMID:
12197223
12.

Low dose intermittent 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in poor risk patients with advanced transitional cell bladder cancer: a pilot study.

Lelli G, Tononi A, Bacchetti P, Maver P, Corrado G, Garofalo F, De Santis P, Pannuti F.

J Chemother. 1989 Aug;1(4):269-71.

PMID:
2809695
13.

Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.

Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.

Jpn J Clin Oncol. 1993 Oct;23(5):291-8.

PMID:
7693990
14.

Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.

Varveris H, Delakas D, Anezinis P, Haldeopoulos D, Mazonakis M, Damilakis J, Metaxaris G, Chondros N, Mavromanolakis E, Daskalopoulos G, Dimitrakopoulos A, Kranidis A.

Anticancer Res. 1997 Nov-Dec;17(6D):4771-80.

PMID:
9494605
15.

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.

Castellano D, Puente J, de Velasco G, Chirivella I, López-Criado P, Mohedano N, Fernández O, García-Carbonero I, González MB, Grande E.

BMC Cancer. 2014 Oct 24;14:779. doi: 10.1186/1471-2407-14-779.

16.

Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.

Ortmann CA, Mazhar D.

Future Oncol. 2013 Nov;9(11):1637-51. doi: 10.2217/fon.13.139. Review.

PMID:
24156324
17.

Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.

Tsavaris N, Kosmas C, Skopelitis H, Dimitrakopoulos A, Kopterides P, Bougas D, Stravodimos K, Mitropoulos D, Alamanis C, Giannopoulos A.

J Chemother. 2005 Aug;17(4):441-8. Erratum in: J Chemother. 2005 Oct;17(5):following 573. Kopteridis, P [corrected to Kopterides, P].

PMID:
16167525
18.

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.

Di Lorenzo G, Buonerba C, Bellelli T, Romano C, Montanaro V, Ferro M, Benincasa A, Ribera D, Lucarelli G, De Cobelli O, Sonpavde G, De Placido S.

Medicine (Baltimore). 2015 Dec;94(51):e2297. doi: 10.1097/MD.0000000000002297.

20.

Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats.

Ozcan A, Korkmaz A, Oter S, Coskun O.

Arch Toxicol. 2005 Aug;79(8):461-5. Epub 2005 Mar 31.

PMID:
15800758

Supplemental Content

Support Center